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Experts’ summary:
Huang and coworkers examined whether radical nephrect-
omy (RN) is associated with an increase in cardiovascular
events and mortality compared with partial nephrectomy
(PN). The study sample was obtained from Surveillance, Epi-
demiology, and End Results (SEER), a consortium of popula-
tion-based cancer registries that includes approximately 26%
of the US population. The primary end points of the analysis
were cardiovascular events, cardiovascular deaths, and all-
cause mortality after renal surgery. The study cohort included
nearly 3000 patients with definitive surgery for a renal tumor
of 4 cm diagnosed between 1995 and 2002.
Of these patients, 18.6% underwent PN and 81.4%
underwent RN. A total of 609 patients had at least one
cardiovascular event after surgery, including 84 (15.1%) in
the PN group and 525 (21.6%) in the RN group. Of the 892
deaths, 173 were attributable to cardiovascular causes. In
the PN and RN groups, 27 (4.9%) and 146 patients (6.0%),
respectively, died of cardiovascular causes. When adjusting
for preoperative demographic and comorbid variables, RN
was associated with 1.4 times more cardiovascular events
after surgery (p < 0.05). However, RN was not significantly
associated with time to first cardiovascular event (hazard
ratio [HR]: 1.21; p = 0.10) or with cardiovascular death (HR:
0.95; p = 0.84).
Experts’ comments:
The interest in PN for small localized renal tumors has
increased in the last decade because it ensures maximal
parenchymal preservation along with oncological efficacy.
Several recent studies showed that for tumors <7 cm, PN
provides excellent cancer-specific survival and recurrence-
free survival rates, equivalent to those achievedwith RN [1–
3]. In contrast, RN invariably leads to a substantial decrease
in the number of glomeruli, and the functional kidney loss is0302-2838/$ – see back matterparticularly relevant if RN is performed for pT1 tumors.
The susceptibility to renal failure is determined, in
large part, by glomerular number: People with fewer
nephrons, whether through reduced endowment or exces-
sive loss such as after RN, have a higher rate of
glomerulosclerosis and fewer nephrons to lose before
their renal excretory function becomes terminally com-
promised [4–7].
A recent publication confirmed that RN represents a
detrimental factor for the development of chronic kidney
disease (CKD), with a 3-yr probability of freedom from new
onset of stage 3 CKD being 80% after PN and 35% after RN
( p< 0.001); corresponding values for stage 4 CKD were 95%
and 64% (p < 0.001), respectively [8]. The limited amount of
functional renal tissue removed by PN causes no or onlymild
adaptive hyperfunction that ismainly related to the duration
of ischemia,while a substantial ablationof renalmass suchas
after RN can cause adaptive hyperfunction and hypertrophy
leading to a statistically significant increase in renal failure
rate [4,8–10].
In the present paper, the authors take a step forward,
trying to evaluate if RN adversely influences nononcological
outcomes through the development of CKD and its associa-
tion with cardiovascular disease. They found that as a
consequence of substantial kidney function loss, RN is
associated with 1.4 times more cardiovascular events after
surgery than PN. RN was not significantly associated with
time to first cardiovascular event (HR: 1.21; p = 0.10) or with
cardiovascular death (HR: 0.95; p = 0.84), but preexisting
renal disease was shown to significantly predict type of
surgery. This finding could have potentially mitigated the
power of the results reported and could explain this lack of
correlation.
The maximal preservation of renal tissue in patients
undergoing surgery for renal tumors is of the utmost
importance for several reasons: The glomerulosclerosis rate
is inversely correlated with the total number of glomeruli;
aging is associated with a significant decline in glomerular
number; many conditions such as hypertension, stone
disease, and diabetes can further affect the kidneys; and
tumors can recur elsewhere in the kidney, such as
contralateral renal cell carcinoma (RCC) [2,3].
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agents increase, the indications for the conservative
management of RCC are expanding. In our department,
PN is performed in 90% and 50% of single sporadic tumors of
<4 cm and 4–7 cm, respectively; thus, the number of PNs
performed has exceeded the number of RNs since 2002 [2].
In conclusion, RN is not the best treatment for most
clinically T1 kidney tumors because it puts patients at risk
of CKD and cardiovascular disease. PN minimizes these
risks, which is a further reason to expand its indications.
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Expert’s summary:
This key paper ties together clinical outcomes in urology with
health economics. The methodology involves source clinical
effectiveness data from systematic reviews previously con-
ducted by the group; treatment cost calculations from the UK
National Health Service (NHS; except for microwave thermo-
therapy, which is virtually obsolete in the United Kingdom
and for which cost was calculated from US manufacturers’
data); and equipment capital costs obtained from commercial
manufacturers.
AMarkovmodelwas constructeddescribing the sequence
of events and main health states that men might find
themselves in after the defined treatment strategies. Effects
were measured by quality-adjusted life years (QALYs) and
costs (in British pounds) at 2006 prices discounted at 3.5%.
Monte Carlo simulation allowed selection of values for each
parameter (95% confidence intervals fromthemeta-analysis)
within the model according to individual dataset, NHS cost
ranges, and expert opinion. Distribution shapes were chosen
according to standard practice before these valueswere used
in the modelling. The perspective was that of the NHS, with
treatments occurring in appropriately equipped units anddelivered by procedure-competent specialist urologists.
The cycle length was set at 3 mo to allow benefit to occur
and short-term adverse events to resolve. A 10-yr time
horizonwas chosen as the period overwhich the population
would be likely to seek active treatment, the current
technologies would remain relevant, and the simulation of
the purchase of new equipment as required would be
possible. The model was run by entering 10 successive
annual cohorts of 25 000 men (the number receiving
treatment each year in the NHS) in England. By choosing a
multiple cohort design, the effects of applying sequences of
escalating treatment and of progressively fewermembers of
a cohort needing additional surgery were also taken into
account. Six health states—treatment, remission, no remis-
sion, remission with incontinence, no remission with
incontinence, and death—were defined. A small possible
drawback was that urethral and bladder neck strictures
were considered to have resolved in 3 mo.
The authors suggested that for urodynamically
obstructed men, monopolar electrovaporisation as a pri-
mary treatment provided the most cost-effective strategy
for surgical treatment of symptomatic benign prostatic
enlargement at a willingness-to-pay threshold of £5000 per
QALY gained. This strategy was sequentially followed by
either holmium laser enucleation (HoLEP) or transurethral
resection (TURP), repeated if necessary on failure or relapse,
with a probability of 0.85 at a willingness-to-pay threshold
of £20,000 per QALY gained. Given uncertainty about the
